Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 170

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 170
---
 directors was aware of and considered those interests,
among other matters, in reaching its decision to approve the PIPE Financing and related matters, including the Subscription Agreement, Registration Rights Agreement and form of Pre-Funded Warrant, and
recommend the approval of the PIPE Financing and related matters to Aadi stockholders. These interests, among other factors, may have influenced the directors and executive officers of Aadi to support or approve the PIPE Financing.

In addition, pursuant to the terms of the Subscription Agreement, the executive officers and directors of the Company have entered into “lock-up” arrangements, which generally prohibit the sale, transfer or other disposition of securities of the Company, subject to certain exceptions, until the shares and shares underlying the Pre-Funded Warrants purchased by the PIPE Investors are registered for resale with the SEC.

- 113 -

CAPITALIZATION The following table sets forth our cash and cash equivalents, short-term investments and capitalization as of September 30, 2024:

| • |     | On an actual basis; and |

| • |     | On an as-adjusted basis to give effect to: (i) the Divestiture,                                                                                                                                                                                    
 including the estimated receipt of $100 million as consideration (which assumes no adjustments under the Divestiture Agreement to the base consideration to be paid at the closing), less $7.3 million in estimated transaction fees and           
 expenses; (ii) the payment in full to WuXi Biologics of the total upfront license fee payment of $44 million pursuant to the License Agreement and related payments of $2.7 million in estimated transaction fees and expenses but                 
 excluding value added taxes related to the license fee payment; and (iii) the issuance and sale in the PIPE Financing of 21,592,000 shares of common stock and 20,076,500 Pre-Funded Warrants to acquire common stock for aggregate gross proceeds 
 of $100 million, less $5.2 million in estimated transaction fees and expenses.                                                                                                                                                                     |

You should read the data set forth in the table below in conjunction with (a) our audited consolidated financial statements and the related notes thereto, (b) our unaudited condensed consolidated financial statements and the related notes thereto, and (c) “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in each case included elsewhere in this proxy statement.

|                                                                                                           |     | September 30, 2024               |          |   |     |             |          |   |
|:----------------------------------------------------------------------------------------------------------|: